financetom
Business
financetom
/
Business
/
SolarEdge's Tough Q3: Revenue Miss, $1 Billion Impairment Charge, Bleak Forecast & More (UPDATED)
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
SolarEdge's Tough Q3: Revenue Miss, $1 Billion Impairment Charge, Bleak Forecast & More (UPDATED)
Nov 7, 2024 11:51 AM

Editor: The title of the story has been updated to reflect the amount of impairment charge.

SolarEdge Technologies ( SEDG ), Inc. shares are trading lower after the company reported third-quarter results yesterday. Revenues were $260.9 million, missing the consensus of $269.38 million.

Revenues from the solar segment were $247.5 million, up 3% from $241.2 million in the prior quarter and down 63% from $676.9 million in the same period last year.

The company shipped 850 Megawatts (AC) of inverters and 189 MWh of batteries for PV applications in the quarter.

Adjusted gross margin was negative 265.4% versus a positive margin of 0.2% in the prior quarter and compared to 20.8% last year.

Adjusted operating loss stood at $808.1 million versus an adjusted operating loss of $114.3 million last quarter.

Adjusted loss per share of $15.33 may not be comparable to the consensus loss of $1.63.

Operating cash flow was negative $63.9 million in the quarter. As of September 30, cash, cash equivalents, bank deposits, restricted bank deposits, and marketable securities totaled $53.3 million.

In the third quarter, SolarEdge ( SEDG ) conducted an asset valuation review, which resulted in a $1.03 billion write-down and impairment of various assets.

Outlook: For the fourth quarter, the company expects revenue of $180 million – $200 million (versus consensus of $308.66 million), revenues from the solar segment of $170 million – $190 million, and adjusted gross margin of negative 4% – 0%.

Investors can gain exposure to the stock via Invesco Solar ETF ( TAN ) .

Price Action: SEDG shares were down 17.3% at $12.13 premarket at the time of writing on Thursday. The stock has recouped all losses and is up 0.31% to $14.73 at the time of update as of 14.15.

Read Next:

Nvidia Partners With AI Startup Hugging Face To Supercharge Open Source Robotics

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Axsome Therapeutics Says It Settled Sunosi Patent Litigation With Unichem Laboratories
Axsome Therapeutics Says It Settled Sunosi Patent Litigation With Unichem Laboratories
Jun 5, 2024
08:27 AM EDT, 06/05/2024 (MT Newswires) -- Axsome Therapeutics ( AXSM ) said Wednesday it has settled patent litigation with Unichem Laboratories regarding Axsome's sleep disorder drug Sunosi. The pharmaceutical company said the litigation, pending in the United States District Court for the District of New Jersey, arose after Unichem applied for the US Food and Drug Administration's approval to...
Montrose Environmental Acquires Canada-based Paragon Soil & Environmental Consulting
Montrose Environmental Acquires Canada-based Paragon Soil & Environmental Consulting
Jun 5, 2024
08:25 AM EDT, 06/05/2024 (MT Newswires) -- Montrose Environmental Group ( MEG ) said Wednesday that it has acquired Paragon Soil & Environmental Consulting, a Canada-based environmental consulting firm. Financial terms of the deal were not disclosed. Price: 43.54, Change: -0.43, Percent Change: -0.98 ...
Mind Medicine Shares Fall After FDA Committee Votes Against Lykos Therapeutics' Psychedelic Drug
Mind Medicine Shares Fall After FDA Committee Votes Against Lykos Therapeutics' Psychedelic Drug
Jun 5, 2024
08:25 AM EDT, 06/05/2024 (MT Newswires) -- Mind Medicine's (MNMD) shares were down 9% in Wednesday's premarket activity, a day after advisers to the US Food and Drug Administration voted against Lykos Therapeutics' psychedelic drug. Lykos Therapeutics said late Tuesday that advisers to the US Food and Drug Administration have voted against its therapy based on the mind-altering drug midomafetamine,...
Calibre Reports Additional Gold Mineralization at Valentine Gold Mine Complex in Newfoundland & Labrador
Calibre Reports Additional Gold Mineralization at Valentine Gold Mine Complex in Newfoundland & Labrador
Jun 5, 2024
08:26 AM EDT, 06/05/2024 (MT Newswires) -- Calibre (CXB.TO), which lost 4% yesterday, on Wednesday highlighted drill results from its 2024 exploration program within its 250-square-kilometer Valentine Gold Mine complex in Newfoundland & Labrador, Canada. Among the highlights, the company reported 2.25 g/t of gold over 15.30 meters estimated true width, including 24.68 g/t of gold over 0.85 meters estimated...
Copyright 2023-2025 - www.financetom.com All Rights Reserved